

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
WO 02/00042 A2

(51) International Patent Classification<sup>7</sup>: A23L 1/30, A61K 31/20

(21) International Application Number: PCT/US01/19828

(22) International Filing Date: 21 June 2001 (21.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/603,626 26 June 2000 (26.06.2000) US

(71) Applicant: THE PROCTER & GAMBLE COMPANY  
[US/US]; One Procter & Gamble Plaza, Cincinnati, OH  
45202 (US).

(72) Inventors: JANDACEK, Ronald, James; 8746 Hollyhock Drive, Cincinnati, OH 45231 (US). KELM, Gary, Robert; 8524 Althaus Road, Cincinnati, OH 45247 (US). BHARAJ, Satinder, Singh; 6697 Raven Crest Drive, West Chester, OH 45011 (US). PENAFIEL, Jorge, Villanueva; 2574 Gazelle Court, Cincinnati, OH 45239 (US).

(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/00042 A2

(54) Title: COMPOSITIONS AND METHODS FOR BODY WEIGHT MANAGEMENT

(57) Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof.

## COMPOSITIONS AND METHODS FOR BODY WEIGHT MANAGEMENT

5

### BACKGROUND OF THE INVENTION

The incidence of obesity in the general population of the United States has shown a dramatic increase over the last decade with over 50% of the population considered overweight or obese. A similar trend is observed in other countries as the so-called Western diet is adopted.

10 Since obesity is associated with a variety of co-morbidities such as diabetes, hypertension, and atherosclerosis, this increase is a major health concern.

A number of approaches have been proposed or used to help subjects reduce food intake, otherwise referred to as energy intake, and thereby manage their body weight. These approaches include use of agents to act on the central nervous system to increase levels of serotonin, and 15 those acting in the gastrointestinal tract to reduce digestion and/or absorption of nutrients. These approaches suffer from potential side effects that reduce their utility for long-term body weight management.

20 A different approach involves the introduction of nutrients directly into the distal small intestine in an attempt to reduce concomitant food intake. This approach uses natural materials and is believed to function via interactions of the nutrients with putative receptors throughout the small intestine, particularly in the distal small intestine (jejunum, ileum) that are believed to participate in the natural mechanisms that induce termination of a meal. This offers the potential advantage of a reduction of side effects due to the use of natural materials and mechanism.

25 Reported data in animals and humans are based on using catheters and naso-gastric tubes respectively, to directly introduce nutrients into their small intestines. Many of the reported studies have employed lipids. For example, infusion of a corn oil emulsion into the small intestine (jejunum or ileum) reduces food intake at a concomitant meal such that total caloric intake (meal plus infusate) is significantly or directionally reduced; see I. Welch, K. Saunders and N. W. Read, Effect of Ileal and Intravenous Infusions of Fat Emulsions on Feeding and Satiety in  
30 Human Volunteers, Gastroenterology 89: 1293-1297, 1985; I. Welch, C.P. Sepple and N. W. Read, Comparisons of the Effects on Satiety and Eating Behavior of Infusion of Lipid into the Different Regions of the Small Intestine, Gut 29: 306-311, 1988; all incorporated herein by reference. Intravenous administration of a triacylglycerol emulsion (Intralipid) failed to reduce total caloric intake in several studies; see I. Welch, K. Saunders and N. W. Read, *id.*; E. K. Walls

and H. S. Koopmans, Effect of Intravenous Nutrient Infusions on Food Intake in Rats, Physiology & Behavior 45: 1223-1226, 1989; all incorporated herein by reference. Pre-meals of triacylglycerol in yogurt also fail to reduce total caloric intake (meal plus pre-meal) at a subsequent meal; see B. J. Rolls, S. Kim, A. L. McNelis, M. W. Fischman, R. W. Foltin, and T.

5 H. Moran, Time Course of Effects of Preloads High in Fat or Carbohydrate on Food Intake and Hunger Ratings in Humans, Am. Journl. Physiology, 260: R756-R763, 1991; J. H. Meyer, M. Hlinka, A. Khatibi and H. E. Raybould, Role of Small Intestine in Caloric Compensations to Oil Premeals in Rats, Am. Journl. Physiology, 275: R1320-R1333, 1998; all incorporated herein by reference.

10 There are many animal studies where nutrients are infused into the small intestine to reduce food intake. For example, Woltman *et al.* have shown that micellar solutions of oleate infused into the duodenum reduced 4-hour food intake in rats to a greater extent than a micellar triolein solution and that duodenal infusion is more potent than ileal infusion in reducing food intake; see T. Woltman and R. Reidelberger, Effects of Duodenal and Distal Ileal Infusions of 15 Glucose and Oleic Acid on Meal Patterns in Rats, Am. Journl. Physiology, 269: R7-R14, 1995; T. Woltman, D. Castellanos and R. Reidelberger, Role of Cholecystokinin in the Anorexia Produced by Duodenal Delivery of Oleic Acid in Rats, Am. Journl. Physiology, 269 R1420-R1433, 1995; all incorporated herein by reference. Greenberg *et al.* have shown that duodenally infused emulsions of triacylglycerol and linoleic acid reduce total caloric intake in a sham feeding 20 rat model, whereas ileal infusions do not; see D. Greenberg, G. P. Smith and J. Gibbs, Intraduodenal Infusions of Fats Elicit Satiety in Sham Feeding Rats, Am. Journl. Physiology, 259: R110-R118, 1990; D. Greenberg, G. P. Smith and J. Gibbs, Intravenous Triglycerides Fail to Elicit Satiety in Sham-Feeding Rats, Am. Journl. Physiology, 264: R409-R413, 1993; D. 25 Greenberg, Fats and Satiety: the Role of the Small Intestine, Appetite 31: 229, 1998; D. Greenberg, Intestinal Satiety, in Satiation from Gut to Brain, G. P. Smith (ed.), pp. 40-70, Oxford University Press, Inc., New York, NY, 1998; all incorporated herein by reference. Other long chain fatty acids (oleic, linolenic) were somewhat less effective.

Meyer *et al.* have conducted a series of studies investigating the effects of infused nutrients upon total caloric intake in rats constrained to three hours of feeding. They found that 30 emulsions of fatty acids greater than 10 carbons in length, solutions of monomeric carbohydrates only with affinity for the glucose transporter, and solutions of the amino acids tryptophan and phenylalanine suppressed total caloric intake when infused in the duodenum or mid-gut (jejunum), or into the colon. These investigators also demonstrated that pre-meals of triacylglycerol failed to suppress total caloric intake in rats constrained to seven hours of feeding;

see J. H. Meyer, M. Hlinka, Y. Tabrizi, N. DiMaso and H. E. Raybould, Chemical Specificities and Intestinal Distributions of Nutrient-Driven Satiety, Am. Journl. Physiology, 275: R1293-R1307, 1998; J. H. Meyer, Y. Tabrizi, N. DiMaso, M. Hlinka and H. E. Raybould, Length of Intestinal Contact on Nutrient-Driven Satiety, Journl. Physiology, 275: R1308-R1319, 1998; all incorporated herein by reference.

More recently, Cox *et al.* have shown that jejunally infused neat linoleic acid or oleic acid (0.2 mL/hr for seven hours) will significantly reduce total daily caloric intake in rats, whereas a long chain triacylglycerol (corn oil) will not. These authors also demonstrated that the reduction is maintained over 20 days of dosing, resulting in a significant difference in weight between treated and control animals; see J. E. Cox, W. J. Tyler, A. Randich, G. R. Kelm, S. S. Bharaj, R. J. Jandacek and S. T. Meller, Suppression of Food Intake, Body Weight, and Body Fat by Jejunal Fatty Acid Infusions, Am. Journl. Physiology, Regulatory Integrative Comparative Physiology, 278: R604-R610, 2000; all incorporated herein by reference.

There are no reported studies known to the inventors in which ingested or gastrically administered nutrients in a pharmaceutical dosage form designed to release the nutrients in the small intestine have been used to reduce food intake. PCT Application WO 87/03198, US Patents 5,322,697, and 5,753,253 disclose using such pharmaceutical preparations for reduction of food intake; all incorporated herein by reference. Infusion data are provided to support these disclosures. However, no data are provided that are derived from the use of enteric nutrient dosage forms designed to release in the small intestine for reducing food consumption and total caloric intake.

Body weight management methods employing natural nutrients to reduce food intake through natural mechanisms are highly sought after. A need still exists for a product comprising nutrient materials that can be ingested by human and animal subjects to reduce consumption of food and lower the total daily caloric intake of the subject.

#### BRIEF DESCRIPTION OF THE INVENTION

The present invention is for compositions, and methods for managing body weight of human and animal subjects using said compositions. The compositions of the present invention comprise satiety agents selected from the group consisting of long chain fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof, wherein said satiety agent releases in the stomach. The compositions are administered prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof. Consuming compositions of the present invention produces a sensation of

satiety in the subjects for a sufficient time wherein the amount of food subsequently consumed is regulated by controlling the subject's appetite.

One objective of the present invention is to provide a safe and effective composition that promotes body weight management of subjects consuming the compositions of the present 5 invention. Said management of body weight can be combined with currently used regimens of diet and exercise for both humans and animals. Another objective is to provide a method for controlling appetite comprising administration of a composition comprising a satiety agent.

#### DETAILED DESCRIPTION OF THE INVENTION

The underlying principle of the present invention is the recognition that ingestion of 10 compositions comprising long chain non-esterified fatty acids, or the non-glyceral esters thereof have the potential to increase hepatic mitochondrial oxidation due to portal absorption of long chain non-esterified fatty acids as such. This may be due to a reduction in the luminal levels of 15 2-monoacylglycerol derived from luminal hydrolysis of triacylglycerol. While not wishing to bound by theory, the inventors believe that appetite control is achieved when there is rapid onset and increased rate of hepatic mitochondrial oxidation of long chain non-esterified fatty acids provided by a compositions of the present invention relative to oxidation of long chain non-esterified fatty acids derived from triacylglycerol that are the primary source of fatty acids in the 20 diet. Appetite control is a primary factor in managing the body weight of subjects.

Hepatic mitochondrial long chain non-esterified fatty acid oxidation rate is, therefore, 25 considered to be an important factor for controlling food intake. For example, rat and human administration of long chain non-esterified fatty acid oxidation inhibitors produce an increase in food intake. This effect is ameliorated by hepatic vagotomy demonstrating that the liver is an important component in this control; see W. Langhans and E. Scharrer, Role of Fatty Acid Oxidation in Control of Meal Pattern, Behavioral and Neural Biology 47: 7-16, 1987; M. I. Friedman, R. B. Harris, H. Ji, I. Ramirez and M. G. Tordoff, Fatty Acid Oxidation Affects Food Intake by Altering Hepatic Energy Status, Am. Journl. Physiology, 276: R1046-R1053, 1999; A. Kahler, M. Zimmermann and W. Langhans, Suppression of Hepatic Fatty Acid Oxidation and Food Intake in Men, Nutrition 15: 819-828, 1999; W. Langhans and E. Scharrer, Evidence for a Vagally Mediated Satiety Signal Derived from Hepatic Fatty Acid Oxidation, J. Autonomic Nervous System 18: 13-18, 1987; all incorporated herein by reference. Thus, it appears that the 30 body attempts to maintain relatively constant levels of long chain non-esterified fatty acids in the blood and that these levels are monitored by the rate of hepatic mitochondrial long chain non-esterified fatty acid oxidation which is transmitted to the brain by vagal afferents. Decreases in hepatic mitochondrial long chain non-esterified fatty acid oxidation lead to increased food intake,

whereas increases lead to a reduction in food intake. Therefore, a composition increasing the rate and extent of hepatic mitochondrial long chain non-esterified fatty acid oxidation will lead to a reduction in food intake and facilitate management of a subject's body weight.

Essentially all long chain fatty acids in the diet are ingested in the form of triacylglycerols. Triacylglycerols are hydrolyzed to long chain non-esterified fatty acids and 2-monoacylglycerols in the lumen of the small intestine. However, the resulting long chain non-esterified fatty acids and 2-monoacylglycerols are re-esterified into triacylglycerols in the enterocytes and formed into small emulsion droplets stabilized by lipoproteins that are termed chylomicrons. Upon exocytosis from the enterocytes, the chylomicrons partition into the lymph vessels instead of the portal vein. Most other nutrients and xenobiotics are absorbed through the portal vein and pass quantitatively through the liver before distribution to the rest of the body. However, since the lymph vessels empty into the blood circulation subsequent to the liver, ingested fatty acids from triacylglycerols are first distributed throughout the body in the form of triacylglycerols. Little of these reach the liver in the form of long chain non-esterified fatty acids during the course of a meal and thus influence food intake.

It is believed that a portion of the long chain non-esterified fatty acids provided by compositions of the present invention is absorbed through the portal vein as long chain non-esterified fatty acids due to a reduction of 2-monoacylglycerols in the lumen of the small intestine. The reduction in 2-monoacylglycerol levels is believed to reduce re-esterification of long chain non-esterified fatty acids in the enterocytes and permit some of the absorbed long chain non-esterified fatty acids to exit the basolateral side of the enterocytes prior to being re-esterified to triacylglycerols and formed into chylomicrons. The long chain non-esterified fatty acids that basolaterally exits the enterocyte as such can partition into the portal vein and thus reach the liver in an oxidizable state quantitatively. This has the potential to greatly increase the rate of hepatic mitochondrial long chain non-esterified fatty acids oxidation relative to a similar amount of fatty acid ingested in the form of a triacylglycerols.

Since distal release of the long chain non-esterified fatty acids is not required in the present invention, there is no need to prepare elaborate enteric dosage forms designed to release the long chain non-esterified fatty acids in the distal small intestine. Thus, the present invention represents a significant improvement over the prior art, which indeed does not contain data demonstrating food intake reduction from such putative enteric dosage forms.

Therefore, the present invention is for compositions, methods of using said compositions and methods for managing the body weight of a subject using said compositions. Body weight

control, particularly weight gain and loss is effectuated by producing a sensation of satiety in said subjects consuming compositions of this invention.

The oral composition of the present invention comprise satiety agents selected from the group consisting of long chain fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof wherein said satiety agent releases in the stomach. Consuming compositions of the present invention induce a sensation of satiety in the subjects for a sufficient time wherein the amount of food subsequently consumed is regulated by controlling the subject's appetite.

Satiety Agents

It has been surprisingly discovered that administration of a satiety agent selected from the group consisting of long chain (greater than 10 carbons) non-esterified fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof in compositions that release said satiety agent in the stomach reduces total caloric intake. This satiety agent may be administered in a wide variety of product forms including non-enteric pharmaceutical dosage forms such as compressed and molded tablets, hard gelatin capsules, soft elastic gelatin capsules, and microcapsules that dissolve in the stomach, emulsions, and suspensions, or as part of a beverage or solid food product. The latter may be used as a meal supplement or replacement. The compositions are administered at a time prior to subsequent consumption of food so as to induce a sensation of satiety in the subjects for a sufficient time wherein the amount of food subsequently consumed is reduced, thus reducing total caloric intake by controlling the subject's appetite. This is believed to be an effective body weight management tool.

The compositions of the present invention comprise satiety agents selected from the group consisting of long chain fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof, wherein said satiety agent releases in the stomach. The long chain fatty acids and their non-glyceryl esters contain from about 12 to about 24, preferably from about 16 to about 18 carbon atoms. The carbon chain has from 0 to about 6, preferably from 0 to about 3 carbon-carbon atom double bonds. The fatty acids are selected from group consisting of lauric acid, lauroleic acid, myristic acid, myristoleic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, margaric acid, stearic acid, dihydroxystearic acid, oleic acid, ricinoleic acid, elaidic acid, linoleic acid, alpha-linolenic acid, dihomogamma-linolenic acid, eleostearic acid, licanic acid, arachidonic acid, arachidic acid, eicosenoic acid, eicosapentaenoic acid, behenic acid, erucic acid, docosahexaenoic acid, lignoceric acid and mixtures thereof.

Preferred fatty acids are selected from the group consisting of oleic acid, linoleic acid and mixtures thereof.

Non-glyceryl fatty acid esters include, but, are not limited to alcohol esters wherein said alcohol portion of the ester is selected from the group of alcohols consisting of methanol, ethanol,

5 n-propanol, isopropanol, n-butanol, isobutanol and mixtures thereof, preferably ethanol.

Preferred non-glyceryl fatty acid esters are selected from the group consisting of ethyl oleate, ethyl linoleate and mixtures thereof.

Method of Body Weight Management

The composition according to the present invention is administered to an animal or human

10 subject at a level of said satiety agent is from about 0.01 grams per kilogram body weight to about 10.0 grams per kilogram body weight, preferably from about 0.04 grams per kilogram body weight to about 1.0 grams per kilogram body weight per serving of said composition to said subject. Animal subjects include, but, are not limited to companion animals such as dogs, cats, horses or other similar animals. The term serving refers to the amount of composition that is  
15 typically consumed at a given time wherein the composition may be in any number of food forms including liquid beverages such as milk shakes, fruit juices or the like, solid food products such as bars, or pharmaceutical dosage forms including compressed and molded tablets, soft and hard gelatin capsules, microcapsules, emulsions, and suspensions. It is preferable wherein said methods are employed in a daily routine over the entire course of a designed or planned weight  
20 management program

The methods for managing the body weight of humans and other animal subjects using compositions of the present invention comprise the step of administration of said composition to the subject at a time prior to food consumption, during food consumption, as a replacement for food consumption and combinations thereof. When taken during food consumption, the  
25 composition of the present invention can be taken separately with the food or can be processed into making a food comprising said composition. Any food consumed or processed with said invention preferably has a maximum triacylglycerol level of about 5 grams. When administered prior to food consumption, the period prior to consumption of food is sufficiently early enough to prevent substantial interaction with any triacylglycerol components of the food being consumed  
30 and to increase hepatic fatty acid  $\beta$ -oxidation and hepatic and celiac vagal activity during said consumption, leading to premature induction of satiety and reduction of energy intake during consumption. Said composition is also believed to be effective in a method for controlling the appetite of a subject.

Generally, administration of the composition of the present invention takes place from about 30 minutes to 6 hours prior to consumption of food. It is preferable that the composition be taken in this period, prior to the subject's primary meals of the day, usually before their morning, mid-day and evening meals.

5 Administration of the composition of the present invention may also replace one or a plurality of the said subject's primary meal or meals.

Additional Ingredients

As previously stated the composition can be made in a plurality of convenient product forms. In this regard, a number of additional ingredients are used in the product formulations to 10 develop a commercially acceptable product such as those previously mentioned herein. One particular favored product form for consumption by humans is a thick, frothy beverage having the consistency of a milk shake. Various optional ingredients to make such a product include suspending agents, flavorants and viscosity modifiers. Other particular product forms include pharmaceutical dosage forms such as tablets. Optional ingredients for tablets include, but are not 15 limited to diluents such as microcrystalline cellulose, absorbants such as colloidal silicon dioxide, disintegrants such as croscarmellose sodium and crospovidone, binders such as povidone, surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, and glyceryl and multiglyceryl fatty acid esters (that do not form 2-monoacylglycerols), and flavors and sweeteners, all at levels appropriate to 20 formulation of suitable tablets that may be compressed using commercial machinery or molded based upon the physical/chemical properties of the selected satiety agent or agents. Hard gelatin capsules may include any of the optional ingredients listed for tablets that may be required to prepare a suitable mass for filling into hard gelatin using commercial machinery. Soft elastic gelatin capsules contain optional ingredients that most typically will include surfactants such as 25 polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, and glyceryl and multiglyceryl fatty acid esters (that do not form 2-monoacylglycerols). In addition to surfactants, optional ingredients in emulsions and suspensions may include hydrocolloids such as methylcellulose, hydroxypropyl methylcellulose, xanthan gum, and guar gum, and flavors and sweeteners.

30

**EXAMPLES**

The following are non-limiting examples of the present compositions which are processed using conventional methods. Such examples of the products are used taken or delivered in a

serving or dose that preferably is consumed in its entirety at a time prior to, concomitant with or in place of the consumption of food. The following examples are provided to illustrate the invention and are not intended to limit the scope thereof in any manner:

Ready-To-Drink Beverage

Ingredients	Example I (%w/v)	Example II (%w/v)	Example III (%w/v)
Mineral Salts	0.0062	0.0062	0.0062
Sodium Hydroxide*	0.0175	0.0175	0.0175
Carageenan <sup>1</sup>	0.0350	0.0350	0.0350
Cellulose gel <sup>2</sup>	0.5200	0.5200	0.5200
Gum Arabic Low Viscosity	0.4100	0.4100	0.4100
Vitamin/Mineral Blend <sup>3</sup>	0.4340	0.4340	0.4340
Lecithin <sup>4</sup>	0.0261	0.0261	0.0261
Mono & Diglycerides <sup>5</sup>	0.0400	0.0400	0.0400
Ethyl Oleate <sup>6</sup>	1.0811	2.1505	3.2432
Cocoa <sup>7</sup>	1.2000	1.2000	1.200
AF Emulsion Antifoam*	0.0020	0.0020	0.0020
Sodium Caseinate <sup>8</sup>	0.2990	0.2990	0.2990
High Heat Nonfat Dry Milk	6.8000	6.8000	6.8000
Maltodextrin <sup>9</sup>	2.4320	—	—
Granulated Sugar	3.9500	3.9500	3.9500
Sucralose Liquid	0.0539	0.0587	0.0587
Vanilla Flavor <sup>10</sup>	0.0015	0.0015	0.0015
Cream Flavor <sup>11</sup>	0.0015	0.0015	0.0015
Vanilla Flavor <sup>12</sup>	0.1000	0.1000	0.1000
QS Water			
Total	100.00	100.00	100.00

5

\* Process aids. Use as needed, up to about level indicated

1 SeaKem CM611 and Viscarin SD389 both from FMC

2 Avicel CL-611 from FMC

3 FT-001106 available from Fortitech

10 4 Centrolex-F available from Central Soya Company, Inc.

5 Myvatex 8-06 available from Quest International USA, Inc.

- 6 05-58405 available from Penta Manufacturing Co., or Crodamol EO from Croda Inc.
- 7 DeZaan D-11-A available from ADM
- 8 Available from DMV International
- 9 Maltodextrin 10 DE (M-100) available from Grain Processing Corporation
- 5 10 Flavor #14896 available from David Michael and Co., Inc.
- 11 Flavor #1967 available from David Michael and Co., Inc.
- 12 Flavor VA03 available from Virginia Dare Extract Co., Inc.

Method of Preparation:

Add approximately 90% of the required water to a batch processor and heat to 130-140°F.

- 10 Add flavors to the storage tank. Recirculate initial water through a liquifier maintaining a level in the liquifier between 1/2 and 2/3 full. Add all ingredients except the flavorings to the liquifier in the order listed above. Add the mono & diglycerides prior to the addition of ethyl oleate. Add the emulsion antifoam prior to sodium caseinate and nonfat dry milk. Stop the flow to the liquifier. Empty the liquifier and flush with 20 pre-measured gallons of water. Route the product from the processor through the heat exchanger, homogenizer, and back through the heat exchanger to the processor. Heat to 170°F (+/-5°F), homogenize at 4500 psi total, 500 psi second stage and cool to less than 45°F. After establishing temperature and pressure for 4 minutes and 30 seconds, divert the flow to the storage tank.

When the product level gets down to one foot in cone bottom processor, put processor in circulation for 4 minutes and 30 seconds to ensure complete homogenization. Take the homogenizer pressure off. Turn the heat off and flush the system with pre-measured water to 95% total batch weight. Mix for twenty (20) minutes before pulling samples for standardizing. After standardizing has been completed (total desired solids) QS with water.

The beverage is sent to package equipment where it filled in the appropriate package. The packaging of these beverages can either be retort or aseptically sterilized. The desired metal beverage cans, such as a DWI Tinplate food can (300 x 315 with 18 beads for a 12oz. serving) would be used for a retort process. A "Dole" type metal can would be used as an example for an aseptic process.

30

**Example IV**

Confectionery Bar

Material	%w/w
High Fructose Corn Syrup	18.0
Honey-Clover	18.0
Defatted Peanut Flour	5.0
Isolated Soy Protein Isolate <sup>1</sup>	28.2
Nonfat Dry Milk <sup>2</sup>	10.0
Brown Sugar	6.0
Ethyl Oleate <sup>3</sup>	14.0
Natural Orange <sup>4</sup>	0.2
Fatty Acid Masker <sup>5</sup>	0.1
Natural Peanut Flavor <sup>6</sup>	0.1
Natural Honey Flavor <sup>7</sup>	0.1
Vanilla Custard Flavor <sup>8</sup>	0.1
Soy Lecithin <sup>9</sup>	0.2
Total	100.0

1 Supro 661 available from Protein Technologies International

2 Low Heat type available from Agrimark

3 Crodamol EO available from Croda, Inc., or 05-58405 from Penta Manufacturing Co.

4 Flavor 57.458/AP SD available from Firmenich

5 5 Flavor 348118 available from Firmenich

6 Flavor 57.304/T available from Firmenich

7 Flavor 598.513/8 available from Firmenich

8 Flavor HC600-137 available from P&G

9 Alcolec S available from American Lecithin Company

10 Method of Preparation:

Weigh and pre-blend all powdered materials in a suitable mixer/blender. Weigh and blend the high fructose corn syrup and honey in a suitable size vessel. Heat the syrup blend to about 90°F. Weigh the ethyl oleate in a suitable size vessel. Weigh and add all the liquid flavors and the soy lecithin to the ethyl oleate: Mix until uniform. To an appropriate size mixer (e.g., 15 Hobart, sigma blade mixer), add the powdered blend, ethyl oleate blend and syrups together. Mix/knead until a uniform texture results.

Slab the batch and cut into bar cores about 57 grams by weight (approximately 1 ½" width, ½" height, 3½" length). Coat or enrobe the bar cores with a milk chocolate or other such

desired coating mixture. Cool the coated bars to room temperature before packaging. Each bar contains about 8 grams of ethyl oleate.

**Example V**

**Molded Tablet**

5 Melt palmitic acid and polyoxyl 40 hydrogenated castor oil and combine in a ratio of 4:1 respectively. Pour the combination or melt into appropriately sized tablet molds wherein each tablet contains about 0.5 g palmitic acid. Cool the molds until solidified and remove tablets from the molds.

**Example VI**

10 **Soft Gelatin Capsule**

Encapsulated neat linoleic acid (technical grade) in a #20 oblong soft gelatin capsule using the standard soft-gelatin ribbon/die process such that each capsule contains about 1 gram of the linoleic acid.

**Example VII**

15 **Hard Gelatin Capsule**

Combine oleic acid (90%) and fumed silica in a ratio of 1:1 using a high shear mixer. Encapsulate the resulting mixture into Size 00 hard gelatin capsules using standard high speed capsule filling machine such that each capsule contains about 0.4 grams of oleic acid.

**Example VIII**

20 **Pharmaceutical Emulsion**

Component	Wt. Pct.
Ethyl Oleate	20.0
Triglyceryl Monooleate	3.0
Polysorbate 80	2.0
Flavor	0.5
Sodium Saccharin	0.2
Purified Water	q.s
Total	100.0

**Method of Preparation:**

Disperse triglyceryl monooleate into ethyl oleate. Dissolve polysorbate 80 into purified water. Emulsify the oil and water solutions using a Microfluidizer (Microfluidics Corp.). Add 25 flavor and sodium saccharin with additional agitation. The emulsion product is packaged into liquid containing packaging such as 500 ml amber glass bottles.

## Example IX

Microcapsules

Component	Wt. Pct.
Gelatin <sup>1</sup>	33.0
Hexameta Polyphosphate	3.0
Eicosapentaenoic acid	59.9
Glutaraldehyde	4.1

5 1 Type A, 275 Bloom available from Knox Gelatin Co.

Method of Preparation:

Dissolve gelatin in about 150 g of purified water at about 55°C. Dissolve the hexameta polyphosphate in 20 g purified water at about 55°C. Emulsify the eicosapentaenoic acid into the gelatin solution under a nitrogen blanket at about 450 rpm. Add about 120 g purified water at 10 about 55°C to the emulsion, maintaining agitation at about 450 rpm. Add the polyphosphate solution to the emulsion. Adjust the pH of the resulting mixture to between 3.5 and 4.5 with glacial acetic acid. Remove heat and allow the mixture to cool slowly to room temperature with continued agitation. Additionally cool the mixture to about 10°C. Add glutaraldehyde and allow 15 cross-linking reaction to occur overnight. Wash resulting microcapsules three times with purified water and filter dry. Package said microcapsules into appropriate packaging such as small volume plastic pharmaceutical vials.

## WHAT IS CLAIMED IS:

1. An oral composition that induces satiety in humans and animals comprising satiety agents selected from the group consisting of long chain fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof wherein said satiety agent releases in the stomach.
2. The composition according to claim 1 wherein said long chain fatty acids and their non-glyceryl esters contain from 12 to 24 carbon atoms with from 0 to 6 carbon-carbon atom double bonds; alternatively 16 to 18 carbon atoms with from 0 to 3 carbon-carbon atom double bonds.
3. The composition according to claims 1-2 wherein the fatty acids are selected from the group consisting of lauric acid, lauroleic acid, myristic acid, myristoleic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, margaric acid, stearic acid, dihydroxystearic acid, oleic acid, ricinoleic acid, elaidic acid, linoleic acid, alpha-linolenic acid, dihomogamma-linolenic acid, eleostearic acid, licanic acid, arachidonic acid, arachidic acid, eicosenoic acid, eicosapentaenoic acid, behenic acid, erucic acid, docosahexaenoic acid, lignoceric acid and mixtures thereof, alternatively from the group consisting of oleic acid, linoleic acid and mixtures thereof.
4. The composition according to claims 1-3 wherein said non-glyceryl fatty acid ester comprises alcohol esters wherein said alcohol portion of the ester is selected from the group of alcohols consisting of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol and mixtures thereof; alternatively selected from the group consisting of ethyl oleate, ethyl linoleate and mixtures thereof.
5. The composition according to claims 1-4 wherein the level of said satiety agent is from 0.01grams per kilogram body weight to 10.0 grams per kilogram body weight per serving of said composition; alternatively 0.04 grams per kilogram body weight to 1.0 grams per kilogram body weight per serving of said composition.

6. A process for making a composition for managing the body weight of humans and other animal subjects comprising the step of administering to said subjects an oral composition comprising a satiety agent selected from the group consisting of long chain fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof wherein said satiety agent releases in the stomach; wherein the total deliverable dosage of said satiety agent to said subject is from 0.04 g per kg body weight to 1.0 g per kg body weight.
7. A process for making a composition according to claim 6 wherein the administration of said composition to said subject replaces one or more of said subject's primary daily meal or meals; wherein the composition may be administered to said subjects in single and plurality of doses or servings daily over the course of a weight management program and is concomitant with consumption of food.
8. A process for making a composition according to claims 6-7 wherein said composition is administered from 30 minutes to 6 hours prior to consumption of food by said subjects; wherein the composition is administered prior to consuming food, said food having a maximum triacylglycerol level of 5 grams.
9. A process for making a composition according to claims 6-8 wherein the subject is a companion animal.
10. A process for making a composition for controlling the appetite of a subject comprising administration of a composition comprising a satiety agent selected from the group consisting of long chain fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof, wherein said satiety agent releases in the stomach; wherein the administration of said composition to said subject replaces one or more of said subject's primary daily meal or meals.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
WO 02/00042 A3

(51) International Patent Classification<sup>7</sup>: A23L 1/30. A61K 31/20, A23L 1/307, A23K 1/18, A61K 31/23; 31/201, 31/202, 31/231, 31/232, A61P 3/04

(21) International Application Number: PCT/US01/19828

(22) International Filing Date: 21 June 2001 (21.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/603,626 26 June 2000 (26.06.2000) US

(71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).

(72) Inventors: JANDACEK, Ronald, James; 8746 Hollyhock Drive, Cincinnati, OH 45231 (US). KELM, Gary, Robert; 8524 Althaus Road, Cincinnati, OH 45247 (US). BHARAJ, Satinder, Singh; 6697 Raven Crest Drive, West Chester, OH 45011 (US). PENAFIEL, Jorge, Villanueva; 2574 Gazelle Court, Cincinnati, OH 45239 (US).

(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
4 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/00042 A3

(54) Title: COMPOSITIONS AND METHODS FOR BODY WEIGHT MANAGEMENT

(57) Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof. The oral composition comprises satiety agents selected from the group consisting of long chain fatty acids, their non-glyceryl esters, hydrolyzable in the presence of gastro-intestinal enzymes, and mixtures thereof wherein said satiety agent releases in the stomach.

## INTERNATIONAL SEARCH REPORT

International Application No:  
PCT/US 01/19828

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	A23L1/30	A61K31/20	A23L1/307	A23K1/18	A61K31/23
	A61K31/201	A61K31/202	A61K31/231	A61K31/232	A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A23G A23K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 003 407 A (EFAMOL LTD) 8 August 1979 (1979-08-08) page 5, line 30 -page 6, line 35 page 3, line 26 -page 4, line 7 page 14, line 14 -page 15, line 7; claims; examples	1-10
X	EP 0 954 975 A (CONLINCO INC) 10 November 1999 (1999-11-10) paragraph '0047!; claims	1-10
X	WO 87 03198 A (ACO LAEKEMEDEL AB) 4 June 1987 (1987-06-04) cited in the application page 2, paragraph 2 -page 5, line 5	1-10

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*8\* document member of the same patent family

Date of the actual completion of the international search

5 February 2002

Date of mailing of the international search report

12/02/2002

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Boddaert, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/19828

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 298 601 A (HOWARD ALAN N) 3 November 1981 (1981-11-03) column 9, line 39 -column 10, line 55; claims -----	1,2,4-8, 10
X	US 5 753 253 A (MEYER JAMES H) 19 May 1998 (1998-05-19) cited in the application the whole document -----	1-10
X	US 5 665 384 A (COURTEILLE FREDERIC ET AL) 9 September 1997 (1997-09-09) claim 8 -----	1,2,4
P,X	US 6 207 638 B1 (PORTMAN ROBERT) 27 March 2001 (2001-03-27) the whole document -----	1-10
P,X	WO 01 17374 A (GHISALBERTI CARLO) 15 March 2001 (2001-03-15) the whole document -----	1-10
X	US 6 034 132 A (REMMEREIT JAN) 7 March 2000 (2000-03-07) claims -----	1,2,6,10
X	EP 0 771 817 A (L V A T S A LAB SA) 7 May 1997 (1997-05-07) abstract; claims -----	1,2,10
P,X	GB 2 355 382 A (GILBERTSON & PAGE LTD) 25 April 2001 (2001-04-25) the whole document -----	1-10

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 01/19828

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0003407	A 08-08-1979	AU 524655 B2 AU 4355179 A CA 1117012 A1 DE 2961102 D1 EP 0003407 A1 IE 47777 B1 JP 1806070 C JP 3069886 B JP 54117035 A JP 6128154 A JP 8032230 B US 4273763 A US 4302447 A US 4444755 A US 4393049 A US 4415554 A	30-09-1982 02-08-1979 26-01-1982 10-12-1981 08-08-1979 13-06-1984 26-11-1993 05-11-1991 11-09-1979 10-05-1994 29-03-1996 16-06-1981 24-11-1981 24-04-1984 12-07-1983 15-11-1983
EP 0954975	A 10-11-1999	US 6214372 B1 US 6060514 A AU 3008399 A AU 3095399 A EP 0954983 A2 EP 0954975 A2 JP 2001508812 T JP 2001508085 T NO 20005565 A NO 20005566 A WO 9956780 A1 WO 9956781 A1 US 6225486 B1 US 2001025113 A1 US 6242621 B1 US 2001031308 A1	10-04-2001 09-05-2000 23-11-1999 23-11-1999 10-11-1999 10-11-1999 03-07-2001 19-06-2001 03-01-2001 03-01-2001 11-11-1999 11-11-1999 01-05-2001 27-09-2001 05-06-2001 18-10-2001
WO 8703198	A 04-06-1987	AU 595276 B2 AU 6724487 A DE 3673998 D1 DK 386287 A EP 0225303 A1 EP 0246294 A1 GR 3000834 T3 JP 2608402 B2 JP 63501425 T PH 23944 A WO 8703198 A1	29-03-1990 01-07-1987 11-10-1990 24-07-1987 10-06-1987 25-11-1987 15-11-1991 07-05-1997 02-06-1988 23-01-1990 04-06-1987
US 4298601	A 03-11-1981	GB 1356370 A AU 5293273 A BE 796331 A1 CA 987587 A1 DE 2310791 A1 FR 2175054 A1 IE 37376 B1 IT 977977 B LU 67165 A1 NL 7303114 A , B, US 4009265 A US 4237118 A	12-06-1974 12-09-1974 02-07-1973 20-04-1976 13-09-1973 19-10-1973 06-07-1977 20-09-1974 22-05-1973 10-09-1973 22-02-1977 02-12-1980

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/19828

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
US 4298601	A		ZA 7301496 A		19-12-1973
US 5753253	A	19-05-1998	US 5322697 A		21-06-1994
			US 6267988 B1		31-07-2001
			AU 684710 B2		08-01-1998
			AU 4400393 A		30-12-1993
			CA 2136871 A1		09-12-1993
			EP 0671907 A1		20-09-1995
			JP 7507546 T		24-08-1995
			WO 9324113 A1		09-12-1993
US 5665384	A	09-09-1997	FR 2660555 A1		11-10-1991
			AT 101512 T		15-03-1994
			CA 2074726 A1		07-10-1991
			DE 69101220 D1		24-03-1994
			DE 69101220 T2		01-06-1994
			DK 523153 T3		09-05-1994
			EP 0523153 A1		20-01-1993
			ES 2062782 T3		16-12-1994
			WO 9115203 A1		17-10-1991
US 6207638	B1	27-03-2001	AU 4176201 A		03-09-2001
			WO 0162086 A1		30-08-2001
			US 2001021694 A1		13-09-2001
WO 0117374	A	15-03-2001	IT MI991894 A1		09-03-2001
			AU 6720000 A		10-04-2001
			AU 6720300 A		10-04-2001
			AU 6720500 A		10-04-2001
			WO 0118161 A2		15-03-2001
			WO 0117374 A1		15-03-2001
			WO 0117498 A1		15-03-2001
US 6034132	A	07-03-2000	JP 11209279 A		03-08-1999
EP 0771817	A	07-05-1997	EP 0771817 A2		07-05-1997
			US 5798348 A		25-08-1998
GB 2355382	A	25-04-2001	NONE		

THIS PAGE BLANK (USPTO)